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Background: Viral respiratory tract infections increase the risk of development and exacerbation of atopic disease. Previously, we demonstrated the requirement for a neutrophil (PMN) subset expressing CD49d to drive development of postviral atopic airway disease in mice. Objective: We sought to determine whether human CD49d
1
PMNs are present in the nasal mucosa during acute viral respiratory tract infections and further characterize this PMN subset in human subjects and mice.
Methods: Sixty subjects (5-50 years old) were enrolled within 4 days of acute onset of upper respiratory symptoms. Nasal lavage for flow cytometry and nasal swabs for viral PCR were performed at enrollment and during convalescence. The Sendai virus mouse model was used to investigate the phenotype and functional relevance of CD49d 1 PMNs. Results: CD49d 1 PMN frequency was significantly higher in nasal lavage fluid during acute respiratory symptoms in all subjects (2.9% vs 1.0%, n 5 42, P <.001). In mice CD49d
1 PMNs represented a ''proatopic'' neutrophil subset that expressed cysteinyl leukotriene receptor 1 (CysLTR1) and produced TNF, CCL2, and CCL5. Inhibition of CysLTR1 signaling in the first days of a viral respiratory tract infection was sufficient to reduce accumulation of CD49d 1 PMNs in the lungs and development of postviral atopic airway disease. Similar to the mouse, human CD49d 1 PMNs isolated from nasal lavage fluid during a viral respiratory tract infection expressed CysLTR1. Conclusion: CD49d and CysLTR1-coexpressing PMNs are present during symptoms of an acute viral respiratory tract infection in human subjects. Further study is needed to examine selective targeting of proatopic neutrophils as a potential therapeutic strategy to prevent development of postviral atopic airway disease. (J Allergy Clin Immunol 2018;142:1206-17.)
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The prevalence of atopic diseases, such as asthma and allergic rhinitis, continues to increase.
1,2 These diseases represent a major burden contributing to increasing health care use and expenditures. 3, 4 Despite these trends, our understanding of the mechanisms involved in the development of allergic diseases, such as asthma, remains limited. Several epidemiologic studies have demonstrated that severe viral respiratory tract infections early in life greatly increase the risk for atopic disease, including asthma, [5] [6] [7] [8] [9] yet the mechanism or mechanisms translating a viral respiratory tract infection into atopic disease and asthma are not fully known. Animal models have revealed several potential mechanistic pathways, but whether these pathways are operative in human subjects is less well known. 10 We have demonstrated that mice infected with Sendai virus (SeV), the murine parainfluenza virus type 1, have postviral atopic disease through a distinct pathway. 11, 12 Infection with SeV drove recruitment of a CD49d-expressing subset of neutrophils (CD49d 1 PMNs), which induced expression of FcεRI, the high-affinity receptor for IgE, on lung conventional dendritic cells (cDCs). 12 Subsequently, anti-SeV IgE was produced, and cross-linking of the cDC-bound IgE led to production of CCL28, a chemoattractant for T H 2 cells. 11 These T H 2 cells produced IL-13, which drove the subsequent mucous cell metaplasia and airway hyperreactivity (ie, development of postviral asthma), all of which depended on the presence of PMNs in the airway. 12, 13 Animal and human studies suggest an important role for PMNs in both viral respiratory tract infections and asthma. Robust PMN influxes have been observed in the airways of infants hospitalized with respiratory syncytial virus (RSV)-induced bronchiolitis or those having wheezing illnesses caused by other respiratory tract viruses, such as parainfluenza, influenza, and rhinovirus.
14 Interestingly, many of these viral infections have been associated with the development of asthma, atopy, or both. 15 PMN numbers are also increased in patients with extant asthma, although their precise pathogenic role is unclear. Our mouse data would suggest that they play an important role in translating viral infections into atopic disease.
The mechanistic pathway we documented in mice appears to function, at least in part, in human subjects. CD49d
1 PMNs are present in human peripheral blood and nasal lavage fluid and associate with allergic disease. 16 Cross-linking IgE on human peripheral blood cDCs leads to production of CCL28. 17 FcεRI expression increases on peripheral blood dendritic cells during a viral respiratory tract infection, as do total serum IgE levels. 18 Although we demonstrated the presence of CD49d
1 PMNs in human subjects, we did not assess whether viral respiratory tract infections were capable of driving accumulation of these CD49d 1 PMNs, as we had seen in our mouse model.
Therefore we sought to determine whether proatopic CD49d
PMNs found in our model are recruited to the airway mucosa during a viral respiratory tract infection in human subjects. We further explored the genetic signature of CD49d-expressing and nonexpressing PMNs and determined whether specific manipulation of PMN subsets can mitigate the development of postviral atopic airway disease in our mouse model.
METHODS
Detailed methods are described in the Methods section in this article's Online Repository at www.jacionline.org.
Human neutrophil subsets in viral upper respiratory tract infection
Asthmatic and nonasthmatic subjects between the ages of 5 and 50 years with symptoms of an upper respiratory tract infection within 4 days of onset were eligible to participate in the study. Subjects with a history of sinus surgery, confirmed immunodeficiency, or autoimmune disease were excluded. The use of an intranasal corticosteroid or antihistamine within 48 hours of presentation, a systemic corticosteroid within 4 weeks, or any biologic or investigational agent also excluded participation. Smoking was not specifically excluded, but participants were instructed to maintain the same smoking status throughout the study. All subjects were enrolled at either the Medical College of Wisconsin Asthma and Allergy Clinic, the Children's Hospital of Wisconsin Emergency Department, or the Froedtert Memorial Lutheran Hospital Emergency Department. The Children's Hospital of Wisconsin Institutional Review Board approved the protocol, and all participants, their parents/guardians, or both provided written consent. An outline of the study design is shown in Fig 1, A. Nasopharyngeal viral swabs and nasal lavage fluid were obtained at the initial (ill) visit and repeated at least 4 weeks later during convalescence (well). Viral swabs were processed for detection of influenza virus A, influenza virus B, RSV, human metapneumovirus, human rhinovirus, and human parainfluenza virus 1 to 4 by using a PCR-based assay. Single-cell suspensions from nasal lavage samples were analyzed for CD49d, CD16, and cysteinyl leukotriene receptor 1 (CysLTR1) expression by using flow cytometry.
Mouse model of postviral asthma
The SeV model was used to characterize the properties of neutrophil subsets (including gene array analysis) and the response to CysLTR1 blockade. Detailed experimental methods are presented in the Methods section this article's Online Repository. For GeneChip, rank product statistics were conducted, and false discovery rates (FDRs) were determined by using RankProd from Bioconductor (http:// www.bioconductor.org/packages/2.12/bioc/html/RankProd.html). Differentially expressed probe sets were defined as those possessing a log 2 fold change between samples of greater than 2 and a P value corrected for an FDR of .01 or less. Data have been submitted to the National Center for Biotechnology Information's Gene Expression Omnibus (accession no. GSE61137).
RESULTS Participants
Sixty subjects were recruited from March 2012 through March 2014. Follow-up visits were obtained from 42 of the 60 subjects through May 2014. Participant flow is summarized in Fig 1, B . Table I shows a summary of the characteristics of the 42 subjects with paired analyses (ie, both ill visit and follow-up convalescence). There were no significant differences in any demographic information between the atopic (n 5 31) and nonatopic subjects (n 5 11). Subjects with virus detected were younger (n 5 23; median age, 17 years; P 5 .046) compared with those in whom no virus was detected (n 5 19; median age, 28 years). Asthmatic subjects (n 5 17) were younger (median age, 10 vs 29 years; P < .001) and predominantly male (65% vs 24%, P 5 .0083) compared with nonasthmatic subjects (n 5 25).
Nasal lavage fluid CD49d
1 PMN frequency increases during acute respiratory illness Fig 2) . Among the 23 subjects with a positive viral PCR result (human rhinovirus, n 5 19; RSV, n 5 3; or influenza virus B, n 5 1), CD49d 1 PMN frequencies were higher during illness compared with convalescence (2.0% [1% to 3.33%] vs 0.0% [0% to 1%], respectively, P < .001; Fig 2) . Atopic status had no effect in the virus-positive subjects because both virus-positive atopic (n 5 16) and nonatopic (n 5 7) subjects demonstrated increased CD49d 1 PMN frequency during the viral illness (atopic: 2.0% vs 0.16%, P 5 .002; nonatopic: 2.76% vs 0%, P 5 .016; ill vs well, respectively; Fig 2) . In contrast, subjects with no virus detected demonstrated an increase in numbers of CD49d 1 PMNs during illness only if they had a history of a positive skin test response or serum specific IgE level (atopic [n 5 15]: 3% vs 1.34%, P 5 .013; nonatopic [n 5 4]: 4.69% vs 2.2%, P 5 .25; ill vs well, respectively; Fig 2) ; however, the lack of significance in the nonatopic group might relate to the small number of subjects (n 5 4) in this group and the fact that a lack of atopy was not verified in this study. Although we hypothesized that asthmatic patients would demonstrate a greater viral infection-induced increase in CD49d 1 PMNs than those without asthma, our data actually showed no difference in these 2 populations (asthmatic patients: 3.1% vs 1.4%, P < _ .05; nonasthmatic subjects: 3.1% vs 1.1%, P < _ .05; ill vs well, respectively; Fig 2) . Furthermore, the presence or absence of virus on nasal swabs had no effect on the increase in numbers of CD49d 1 PMNs seen with or without asthma (Fig 2) . Similar results were seen when comparing absolute numbers of CD49d
1 PMNs between all of these groups (see Fig E1) .
Subjects with asthma were noted to have lower FEV 1 at the time of respiratory symptoms (se Fig E2, A, in this article's Online Repository at www.jacionline.org), and this difference was most marked in those undergoing an asthma exacerbation at the time of illness (see Fig E2, B) asthma exacerbation, the frequency of CD49d 1 PMNs was not noted to be different (see Fig E2, C) jects, including those with a positive or negative viral PCR result. This increase was also seen in both atopic (n 5 31) and nonatopic (n 5 11) subjects who were confirmed to have a virus detected (n 5 7 virus detected and nonatopic; n 5 16 virus detected and atopic); however, among subjects in whom a virus was not detected, this increase occurred only among atopic subjects (n 5 4 for virus not detected and nonatopic; n 5 15 for virus not detected and atopic). Asthma status (n 5 17 with asthma; n 5 25 without asthma) did not alter the increase in CD49d 1 PMN numbers with illness nor did the detection of virus (n 5 11 with asthma; n 5 12 without asthma). However, among subjects in whom a virus was not detected, this increase occurred only among subjects who did not have asthma (n 5 6 with asthma; n 5 13 without asthma).
Boxes represent 25th-75th percentiles of data, with the median indicated by a line. Whiskers were plotted with the Tukey method, and outliers are shown as individual circles. For all panels, the Wilcoxon signedrank test was used to compare the median frequency of CD49d 1 PMNs between ill and well subjects. A P value of less than .05 was considered significant. *Results were still significant after multiple test adjustment by using the step-down Bonferroni method.
J ALLERGY CLIN IMMUNOL VOLUME 142, NUMBER 4 in all subjects (top panel: n 5 25 without asthma; n 5 17 with asthma) or in those in whom a virus was detected (middle panel: n 5 12 without asthma; n 5 11 with asthma) or was not detected (lower panel: n 5 13 without asthma; n 5 6 with asthma). Boxes represent the 25th to 75th percentiles of data, with the median indicated by a line. Whiskers were plotted with the Tukey method, and outliers are shown as individual circles. For all panels, the Mann-Whitney U test was used to compare median frequency of CD49d 1 PMNs between the 2 groups on each panel. A P value of less than .05 was considered significant. *Results were still significant after multiple test adjustment using the step-down Bonferroni method.
This study was designed to compare the frequency of CD49d 1 PMNs in the nasal lavage fluid of subjects during and after symptoms of a viral upper respiratory tract illness (ie, a paired analysis, as described above). However, using unpaired analyses, we can examine the effect of viral detection, atopy, and asthma status on the frequency (Fig 3) PMNs during the acute illness and during convalescence.
The identification of a virus by using PCR did not differentiate the frequency or absolute number of CD49d 1 PMNs during the acute illness (Fig 3, A , and see Fig E3, A) ; however, during convalescence, there were fewer (frequency and absolute numbers) CD49d
1 PMNs in the lavage fluid of subjects for whom a virus was detected by using PCR. This difference held regardless of atopic status for the frequency; however, in nonatopic subjects absolute numbers of CD49d 1 PMNs on convalescence did not vary with viral status (see Fig E3, A) .
Our previous publication found the frequency and total number of CD49d
1 PMNs differentiated atopic and nonatopic subjects at baseline. 16 However, in our current study no significant difference was found between the numbers (Fig 3, B) or frequencies (see Fig  E3, B) of CD49d 1 PMNs in atopic and nonatopic subjects. The detection of virus during upper respiratory tract infection symptoms did not change this lack of discrimination. Similarly, asthma status did not affect the frequency (Fig 3, C) or absolute number (see Fig E3, C) of CD49d 1 PMNs in nasal lavage fluid, regardless of virus detection.
Characterization of murine PMN subsets based on CD49d expression
To better characterize differences between CD49d-expressing and nonexpressing PMNs, we turned to our mouse model of postviral atopic disease. PMNs were isolated from bronchoalveolar lavage (BAL) fluid 3 days after inoculation with SeV and flow sorted based on CD49d expression, with resulting populations being greater than 95% pure. The transcriptomes of the resulting CD49d 1 and CD49d 2 PMNs were then compared. The gene product expression of the 2 groups differed by only approximately 670 gene products (Fig 4, A) . Fig 4, (Fig 4, C) . We next assessed whether there was differential protein expression between these 2 PMN subsets. We examined cytokines produced by the cytokine array, and as shown in Fig 4, D, CD49d   1 PMNs produced significantly higher TNF, CCL2, and CCL5 levels. Despite significant cell death after 24 hours of culture (viability determined by using Trypan Blue exclusion: 29% 6 6% for CD49d
1 PMNs and 5% 6 1% for CD49d 2 PMNs), there were sufficient functional PMNs in both groups for similar production of CCL3. However, by using a dihydrorhodamine assay, we found that in PMNs freshly isolated from an SeV-infected mouse, the oxidative burst was significantly greater for CD49d 1 PMNs (Fig 4, E and F) . The difference appears to be a deficient oxidative burst in CD49d
2 PMNs from SeV-infected animals because PMNs from LPS-inoculated mice, all of which were CD49d 2 (data not shown and Cheung et al 12 ), demonstrated an oxidative burst similar to that seen with CD49d
1 PMNs from SeV-infected animals.
CysLTR1 blockade reduces CD49d 1 PMN accumulation in SeV infection
The expression of Cysltr1 on CD49d
1 PMNs was intriguing because a prior study had shown that a fraction of human PMNs in nasal lavage fluid during seasonal allergic rhinitis expressed both message and protein for CysLTR1. 20 Therefore we examined whether CysLTR1 was actually expressed on the surfaces of CD49d 1 PMNs isolated from BAL fluid using flow cytometry. As shown in Fig 5, A, CysLTR1 was expressed exclusively on CD49d 1 PMNs. Importantly, the CD49d PMNs did not express the eosinophil markers CCR3 or Siglec-F (data not shown). RSV infection has been reported to induce significant amounts of cysteinyl leukotrienes (CysLTs), 21 and therefore we next examined whether CysLTs were generated during SeV infection. CysLT levels were increased in BAL fluid by day 3 after inoculation with SeV and followed the increase in CD49d
1 PMNs in BAL fluid (Fig 5, B) . Furthermore, the viability of CD49d 1 but not CD49d
2 PMNs was increased with leukotriene (LT) D 4 addition in vitro (Fig 5, C) . To examine whether LTD 4 could reduce apoptosis and increase the viability of CD49d 1 PMNs in vivo, mice were given LTD 4 or PBS intranasally 36 hours after inoculation with SeV, and lung PMNs were examined 12 hours later (ie, 12 hours after LTD 4 or PBS administration). As shown in Fig 5, D , administration of LTD 4 led to increased viability and reduced apoptosis of CD49d 1 but not CD49d 2 PMNs. Furthermore, treatment on days 1 and 2 after inoculation with SeV with the CysLTR1 antagonist pranlukast led to a significant increase in apoptosis (ie, Annexin V/propidium iodide [PI] staining) of the CD49d 1 PMNs on day 3 after inoculation with SeV but had no effect on apoptosis of CD49d 2 PMNs (Fig 5, E) . If CysLTR1 functioned as a survival or recruitment signal for CD49d
1 PMNs, we hypothesized that blockade of this receptor would reduce the frequency and number of CD49d 1 PMNs after inoculation with SeV. Therefore, using pranlukast, we examined the effect of CysLTR1 blockade during SeV infection. Pranlukast administration during the first 2 days after inoculation with SeV led to decreased absolute numbers and frequencies of CD49d 1 PMNs in the BAL fluid (Fig 6, A, left) . However, we saw no change in lung frequencies or numbers of CD49d-expressing PMNs (Fig 6, A, right) . These data indicate that CysLTR1 signaling is important for airway accumulation of CD49d 1 PMNs during SeV infection. Repeating the experiment by using Ly6G rather than Gr-1 expression to identify PMNs generated similar results (Fig 6, B , and data not shown).
CysLTR1 blockade attenuates post-SeV lung disease
Because CysLTR1 blockade reduced the frequency and number of CD49d
1 PMNs in BAL fluid during SeV infection, we hypothesized that a similar blockade early during the antiviral response (ie, when PMNs are being recruited) 22 would decrease development of postviral asthma. Indeed, when pranlukast was administered during just the first 5 days after inoculation with SeV, both postviral mucous cell metaplasia (Fig 6, C) and airway hyperreactivity (Fig 6, D) were attenuated. Because T H 2 cells can respond to CysLTs, treatment with pranlukast might have inhibited their migration or function. 23 To affirm that the effects of CysLTR1 blockade were not related to adaptive immune cells or stromal cells, such as airway smooth muscle cells, which might also respond to CysLTs, 24 we administered pranlukast daily from days 12 to 18 after inoculation with SeV, the time points when blockade of IL-13 and T H 2 cells have been shown to attenuate post-SeV atopic disease. 13 Treatment with pranlukast at these later time points did not alter the development of postviral disease (Fig  6, E and F) . Therefore we conclude that CysLTs through innate cells, most likely CD49d 1 PMNs, are necessary for the development of postviral atopic airway disease in our model.
Human CD49d
1 PMNs express CysLTR1
Finally, we examined whether CysLTR1 expression can be seen on CD49d
1 PMNs in human subjects. As shown in Fig 6, 
Because all of the PMNs tested came from atopic subjects (3 male subjects and 1 female subject), we were unable to determine whether CD49d
1 PMN expression of CysLTR1 is an atopic phenomenon or a general feature of the human CD49d 1 PMNs.
DISCUSSION
Our prior work outlined a mechanistic pathway translating a viral respiratory tract infection into atopic disease. 11, 12 In this report we have further characterized the CD49d-expressing PMN cohort and found that although most of their gene products are similar to traditional CD49d 2 PMNs, there were several marked differences. Key among these is expression of the receptor for CysLT, CysLTR1. We found that this receptor is expressed on both murine and human CD49d
1 PMNs and that, in the case of mice, signaling through this receptor increases viability of the CD49d 1 PMNs. Furthermore, CysLTR1 signaling early in a viral infection is critical for translation of the viral infection into atopic disease because treatment with a CysLTR1 antagonist early but not late in the SeV model prevented postviral airway hyperreactivity and mucous cell metaplasia. These studies further define the mediators involved in translation of a viral respiratory tract infection into postviral atopic disease, including asthma, and they provide a rationale for studying these pathways in human subjects.
Interestingly, in our human study we were able to demonstrate that numbers of CD49d 1 PMNs increase in nasal lavage fluid during acute upper respiratory symptoms but that, unlike in the mouse, this did not require documentation of a viral respiratory tract infection. Because we previously reported that CD49d PMNs are associated with atopic responses, this is not that surprising and might explain why in subjects with negative viral PCR results the increase in numbers of CD49d
1 PMNs was only significant in atopic subjects. 16 In fact, because subjects were enrolled based on symptoms, it is possible that some of the atopic subjects were having allergic rhinitis symptoms rather than a viral infection. However, our subgroup analysis in this study found that CD49d 1 PMNs do not differentiate atopic and nonatopic subjects. This is in contrast to our prior study, which showed significantly increased numbers of CD49d 1 PMNs in the lavage fluid (and blood) of atopic subjects at baseline. 16 A possible explanation for this discrepancy is how nonatopic status was defined in the 2 studies. In our prior study we verified the nonatopic status of subjects, something that was not done for this study (ie, the lack of any history of a positive skin test result or serum specific IgE level was equated with nonatopic status, whereas in the prior study all subjects underwent skin testing as part of the study). Furthermore, we showed in the previous publication that CD49d 1 PMNs increase in nasal lavage fluid after an allergen challenge. Therefore it is possible that some of our subjects in this study were exposed to allergens to which they were allergic and that exposure might have been different between the initial presentation (ie, the ill visit) and 6 weeks later.
We acknowledge that there are limitations to this study. For example, the number of nonatopic subjects with negative viral assay results was small; the study was not powered to test the role of atopy, asthma, or viral status on CD49d
1 PMN frequencies/ numbers; and subjects without confirmed viral respiratory tract infections might have had other triggers of symptoms, such as bacterial or viral infection, not captured by the PCR assay.
An additional limitation of our study is the lack of transcriptome analysis of human PMN subsets. We ended up focusing on the mouse model because the yield of viable PMNs from nasal lavage fluid was too low to allow for useful sorting (data not shown). Furthermore, our mechanistic model is based on the airway (upper and/or lower), and we did not believe that human peripheral blood PMN transcriptomes would accurately reflect those of the airway.
Using our mouse model, we demonstrated significant functional differences between CD49d 1 and CD49d 2 PMNs. These findings provide additional evidence that PMN subsets are distinct and in the mouse that CD49d 1 PMNs are more ''proatopic.'' In fact, the cytokines/chemokines exclusively produced by CD49d 1 PMNs (TNF, CCL2, and CCL5) have all been associated with atopic disease. TNF has been shown to be a key mediator for T H 2 development in a model of viral pathogen-associated molecular pattern-induced airway inflammation, 25 and both CCL2 and CCL5 are T H 2 chemoattractants that increase during viral respiratory tract infections. 26, 27 The differential transcriptome and cytokine/chemokine profiles further argue for the idea that CD49d treated as in Fig 6, A, but BAL fluid PMNs were identified by using Ly6G (instead of Gr-1) and CD49d staining (n 5 6). C and D, Pranlukast from day 21 to day 5 after inoculation with SeV significantly reduced postviral atopic disease, as evidenced by mucous cell metaplasia (Fig 6, C) and airway hyperreactivity (Fig 6, D) at day 21 after inoculation with SeV (n 5 5-6 per group). This effect was not seen in mice inoculated with UVinactivated SeV. E and F, Pranlukast treatment after viral clearance (days 12-18 after inoculation with SeV) did not reduce mucous cell metaplasia (Fig 6, E) or airway hyperreactivity (Fig 6, F) by day 21 after inoculation with SeV (n 5 5 per group). G, Human CD49d 1 PMNs express CysLTR1. Representative plots and histograms with fold change mean florescence intensity (MFI) for CysLTR1 staining of nasal lavage cells from human subjects within the first 4 days of viral upper respiratory tract infection symptoms (n 5 4). The Student t test was used for Fig 6, A-C , E, and G, and ANOVA with the Tukey multiple comparison test was used for Fig 6, D and F. Mch, Methacholine; ns, not significant.
CD49d
1 PMNs was surprising. Eosinophils also express CD49d and CysLTR1; however, our CD49d 1 PMNs did not express either of the eosinophil markers CCR3 or Siglec-F. 29 Moreover, our previously published cytospin preparations clearly demonstrate PMN morphology in both CD49d 1 and CD49d
2
PMNs. 12 Interestingly, CysLTR1 expression has been noted in a subset of nasal lavage fluid PMNs in human subjects with allergic rhinitis. 20 However, whether these PMNs express CD49d is unknown. Therefore we conclude that there is a subset of PMNs, both in mice and human subjects, that express CysLTR1 and, at least in the context of a viral infection, CD49d.
The CysLTR1 receptor seems to be functionally important because pranlukast administration during the first 2 days after inoculation with SeV decreased absolute numbers and frequencies of BAL fluid CD49d 1 PMNs. However, this effect was limited to BAL fluid because the number of CD49d 1 PMNs in the lung was unchanged by CysLTR1 blockade. The disparate effect of pranlukast on BAL fluid versus lung tissue suggests that reduction of BAL fluid CD49d 1 PMN numbers is not completely due to decreased recruitment to the BAL fluid because we would expect this to have increased lung CD49d 1 PMN numbers. One explanation could be that CysLTs provide a survival signal that keeps BAL fluid CD49d
1 PMNs alive once they have migrated out of the lung. Supporting this view are our data that demonstrate increased viability in CD49d
1 PMNs when cultured with LTD 4 . Our prior work demonstrated that CD49d
1 PMNs drive FcεRI expression on lung cDCs after a 48-hour cognate interaction. 12 Therefore it is possible that the loss of postviral atopic disease with pranlukast treatment resulted from reduced viability of CD49d 1 PMNs, preventing them from fully interacting with cDCs.
The role of CysLTR1 and PMNs appears to depend on the stimulus used to drive airway disease. Unlike our viral model, in which CysLTR1 appears to increase the level of disease through CD49d
1 PMNs, a model of irritant-induced asthma demonstrated the apparent opposite. 30 Mice exposed to Cl 2 had lung neutrophilia that was associated with increased CysLT levels. Unlike our model, inhibition of CysLTR1 signaling led to increased airway disease, which could be prevented by depletion of PMNs. Although the authors did not examine PMN subtypes, it is intriguing to speculate that Cl 2 -induced disease is driven by CD49d 2 PMNs, with the CD49d 1 PMNs possibly being protective. Although perhaps not surprising, the type of stimulus driving airway disease might well tune the PMN response. CD49d 1 PMNs have been reported in human disease, 31 and CysLTs have been shown to increase b 2 -integrin activation and adhesion in human PMNs in vitro. 32 However, no human studies have addressed whether CysLTR1 is exclusively expressed on CD49d 1 PMNs. We examined the nasal lavage fluid of human subjects within 4 days of onset of viral upper respiratory tract infection and found expression of CysLTR1 on CD49d 1 but not CD49d 2 PMNs. These results, combined with our prior work demonstrating CD49d
1 PMNs in the peripheral blood and nasal lavage fluid of atopic subjects, support further investigation into the role these PMNs play in human disease. 16 To our knowledge, this is the first report documenting functional differences between 2 PMN subsets during a viral respiratory tract infection. Development of postviral atopic disease requires the ''alternative'' CD49d 1 PMNs, whereas ''classical'' CD49d PMNs do not appear to play a critical role in our SeV model. We have demonstrated the feasibility of manipulating proatopic PMN subset accumulation during a viral respiratory tract infection to significantly diminish development of postviral airway disease. This might have clinical implications because current therapies either do not target the PMNs or affect their activities in a nonspecific way that can lead to potential harm. 33 Given that other components of the SeV model are intact in human subjects, we believe the demonstration of CysLTR1 expression on human CD49d
1 PMNs might have therapeutic implications. One human study showed a clinical benefit to starting CysLTR1 antagonism (montelukast) early in children with RSVinduced bronchiolitis but without pre-existing asthma. 34 However, later trials with montelukast in postviral wheezing or asthma exacerbations did not show efficacy. 35, 36 We would expect these different responses because in our model CysLTR1 blockade only prevented postviral disease when given before symptoms of disease (ie, days 21 to 5 after inoculation with SeV), whereas treatment after viral clearance (days 12-18 after inoculation with SeV) had no effect on postviral disease.
In summary, our study begins to define an alternative PMN subset (based on expression of CD49d, CysLTR1, TNF, CCL2, and CCL5) that is needed for full development of postviral atopic disease. Expression of CysLTR1 on CD49d
1 PMNs is functional because culture with LTD 4 increased their in vitro survival and specific CysLTR1 antagonism reduced accumulation of these cells in BAL fluid and blocked the subsequent development of postviral disease. In human subjects numbers of CD49d 1 PMNs increased in nasal lavage fluid during an acute viral respiratory tract infection and coexpressed CysLTR1. Therefore our work suggests further studies are needed to identify strategies that alter accumulation of CD49d 1 PMNs in the airways and to ultimately determine their role in development of postviral atopic disease.
METHODS

Personal medical history
Subjects were classified as atopic based on a positive aeroallergen skin or serum specific IgE test result to at least 1 allergen with clinical correlation, as documented in the medical record. Subjects were classified as asthmatic based on a physician's diagnosis, as documented in the medical record. Asthma exacerbation was defined as a decrease in FEV 1 from baseline or symptoms requiring frequent b-agonist use or subsequent treatment with a systemic corticosteroid as documented at the time of enrollment or by telephone interview 1 week after enrollment because symptoms of an asthma exacerbation could have been delayed after our enrollment timeframe (ie, within 4 days of upper respiratory symptom onset). Of the 12 subjects who met the criteria for an asthma exacerbation, only 2 subjects were not prescribed oral corticosteroids within 1 week of their ''ill'' visit.
Nasopharyngeal swab
A nasopharyngeal swab was performed according to the manufacturer's instructions and collected in transport medium (M4; Remel, Thermo Fisher Scientific, Lenexa, Kan). Swabs obtained were stored at 2808C and sent to the Children's Hospital of Wisconsin clinical laboratory in batches for PCR-based viral assays. Viruses tested were as follows: influenza A, influenza B, RSV, human metapneumovirus, human parainfluenza virus 1, human parainfluenza virus 2, human parainfluenza virus 3, human parainfluenza virus 4, and human rhinovirus. This technique of collecting swab samples in transport medium, freezing, and analyzing in batches is an approach validated by our clinical laboratory to preserve sensitivity of the viral assays.
Nasal lavage
Nasal lavage was performed in all subjects at enrollment to assess the neutrophilic presence in the respiratory mucosa, as previously reported. E1 The collected fluid was processed immediately and analyzed by using flow cytometry for determination of CD49d 1 PMNs, as outlined below.
Convalescent visit
All subjects were asked to return at least 4 weeks after the initial visit (''convalescence'') for identical testing, which included a Sino-Nasal Outcome Test (SNOT-20) questionnaire, spirometry, nasopharyngeal swab, and nasal lavage.
Lavage processing
Nasal lavage fluid was processed immediately to yield a single-cell suspension, as previously published.
E1
Mouse studies
Male C57BL6 mice (6-20 weeks old; Jackson Laboratory, Bar Harbor, Me) were used for all experiments. Mice were housed and handled and experiments were performed according to protocols approved by the Institutional Animal Care and Use Committees at both the Medical College of Wisconsin and the Research Institute at Nationwide Children's Hospital.
Mice were inoculated intranasally with 2 3 10 5 plaque-forming units (in 15 mL) of SeV (Strain 52; American Type Culture Collection, Manassas, Va) or UV-inactivated SeV. UV-inactivated SeV was used as a control because UVexposure makes the virus incapable of infecting mice but provides a way to administer the same amount of initial protein as live SeV. Mice in all groups were monitored daily for weight and activity. In some experiments pranlukast (25 mg/kg; Sigma, St Louis, Mo) in dH 2 O was administered by means of gavage daily from days 21 to 5 after inoculation with SeV or from days 12 to 18 after inoculation with SeV; control mice were given dH 2 O by means of gavage (200 mL). On day 21 after inoculation with SeV, airway resistance was measured and mice were euthanized, with their lungs harvested for evaluation of mucous cell metaplasia.
BAL fluid and single-cell suspensions from lung digests were obtained on day 3 after inoculation with SeV, as previously described. E2 Briefly, mice were sacrificed, the inferior vena cava was severed, and the right cardiac ventricle was injected with PBS before BAL was performed with 1 mL of PBS. Lungs were removed, minced, and incubated in digest medium for 1 hour at 378C, and EDTA was added to the medium (2 mmol/L final concentration) for the last 15 minutes. The single-cell suspension was filtered through 40-mm-pore cell strainers before removing erythrocytes by using hypotonic lysis.
To determine the effect of LTD 4 administration on PMN apoptosis in vivo, mice were given 30 mL of PBS or LTD 4 (40 pg/mL) intranasally 36 hours after inoculation with SeV, and 12 hours later, lung PMNs were isolated and viability was determined by using either Trypan Blue (Gibco, Grand Island, NY) exclusion or Annexin V/PI staining with flow cytometry. For the effect of CysLTR1 blockade on PMN apoptosis, mice were inoculated with SeV intranasally, and on days 1 and 2 after inoculation with SeV, 200 mL of vehicle or pranlukast (25 mg/kg) was administered by means of gavage. On day 3 after inoculation with SeV, lung PMN apoptosis was assessed by using Annexin V/ PI staining.
Antibodies and flow cytometry
Phycoerythrin-, allophycocyanin-, fluorescein isothiocyanate-, or Alexa Fluor 647-labeled antibodies against mouse CD49d (clone R1-2), Gr-1 (clone RB6-8C5), and Ly6G (clone 1A8); human CD16 (clone 3G8) and CD49d (clone 9F10); and isotype control IgGs were obtained from eBioscience (San Diego, Calif), BD PharMingen (San Jose, Calif), BioLegend (San Diego, Calif), and/or Invitrogen (Carlsbad, Calif). Rabbit polyclonal antibody against mouse CysLTR1 and fluorescein isothiocyanate-labeled goat antibody against rabbit IgG were obtained from Abcam (Cambridge, United Kingdom). Stained cells were analyzed with a FACSCalibur flow cytometer (BD Biosciences), and data were analyzed with FlowJo software (TreeStar, Ashland, Ore). In some experiments cells were stained with mAbs and then sorted through the FACSAria Cell Sorter to obtain PMN subsets (purity of both subsets was >95%).
Oxidative burst
BAL fluid PMNs were isolated from mice 3 days after inoculation with SeV or 1 day after LPS, and flow sorting was used to isolate Gr-1 1 /CD49d
PMNs. By using a commercial dihydrorhodamine assay (Cayman, Ann Arbor, Mich), according to the manufacturer's instructions, the oxidative burst was determined with flow cytometry. For some samples, phorbol 12-myristate 13-acetate (200 nmol/L) was added for 45 minutes to maximize oxidative burst.
Transcriptome
RNA was amplified/labeled with the Express Kit (Affymetrix, Santa Clara, Calif) and hybridized to the Affymetrix Mouse Genome 430_2.0 Array per the manufacturer's protocol. Image data were quantified with Affymetrix Expression Console Software and normalized with Robust Multichip Analysis (www.bioconductor.org/) to determine signal log ratios.
Real-time PCR assay
mRNA was isolated with TRIzol (Sigma-Aldrich) from which cDNA was generated with the QuantiTect Reverse Transcription Kit (Qiagen, Hilden, Germany), according to the manufacturer's instructions. Quantitative realtime PCR assays were performed with TaqMan Fast Universal PCR Master Mix and the StepOnePlus PCR system (Applied Biosystems, Foster City, Calif). All quantitative real-time PCR data are presented as copy number normalized to Gapdh copy number. TaqMan primer and probes for rodent Gapdh (4352339E), Cysltr1 (Mm00445433), Ccl2 (Mm00441242), Ccr2 (Mm00438270), Mmp9 (Mm00442991), and Cxcr2 (Mm00438258) were obtained from Applied Biosystems.
Cell-culture experiments for cytokine or viability measurements
Flow-sorted populations of PMNs (purity >95%) were cultured in complete RPMI 1640 supplemented with penicillin/streptomycin, gentamicin, L-glutamine (Invitrogen), and 10% FCS (Atlanta Biologicals, Flowery Branch, Ga) for 24 hours at 378C and 5% CO 2 . Cells were plated at 10 5 cells/well in 200 mL of medium in a 96-well round-bottom plate (Corning, Corning, NY). In some experiments LTD 4 was added at 0, 20, or 100 pg/mL (Sigma-Aldrich). Viability was determined by using Trypan Blue stain exclusion (Gibco) and/ or Annexin V/PI staining.
Cytokine microarray
Supernatants from cultured PMNs were plated in duplicates on an ELISAbased cytokine array plate to measure levels of IL-4, IL-5, IL-6, IL-10, IL12p70, IL-17, TNF, IFN-g, GM-CSF, CCL2, CCL3, CCL5, CCL17, and CXCL1 (catalog no. 104750GR; Quansys Biosciences, Logan, Utah). The array was developed on the LI-COR Odyssey (LI-COR Biosciences, Lincoln, Neb), according to the manufacturer's instructions, and analyzed with QView software (Quansys Biosciences).
Histochemistry
Mouse lung tissue (at 25 cm H 2 O pressure) was fixed in 10% zinc formalin and processed by the Children's Research Institute Histology Core for standard hematoxylin and eosin and periodic acid-Schiff staining. Quantification of mucous cells was performed by a blinded observer counting the number of periodic acid-Schiff-positive cells per millimeter of basement membrane using Image J software (National Institutes of Health, Bethesda, Md), as previously reported. E3 
Airway reactivity measurements
Noninvasive measurements of airway hyperreactivity (specific airway resistance [sRaw]) after exposure to nebulized vehicle (PBS) or doubling concentrations of methacholine (10-160 mg/mL) were performed by using the FinePointe NAM double-chamber plethysmography system (Data Sciences International, New Brighton, Minn), according to the manufacturer's instructions and as we have previously reported. E4 Briefly, the FinePointe NAM system uses a restrained 2-chamber design. After daily calibration of the system, a collar is placed around the neck of the conscious mouse, which is then inserted into the chamber (our system has 4 chambers and can analyze 4 mice at once). The collar divides the chamber into 2 sections, essentially separating the head from the body. This allows the NAM system to independently measure nasal and thoracic flow and the phase difference between the 2, which provides the measurement of airway resistance in conscious animals. Once placed in the chamber, the mice are exposed to 10 mL of nebulized PBS or various concentrations of methacholine over 30 seconds. Data (sRaw) are then collected over 3 minutes after the nebulization. After a 30-second recovery period, the next dose of methacholine is administered. The FinePointe NAM software then exports the mean sRaw for each dose (data averaged over the 3-minute period of acquisition). We acknowledge that these measurements of sRaw might not reflect airflow in the lower airways because changes in the upper airways could potentially add to the measured sRaw. However, the 2-chamber design has been shown to provide discrimination between upper and lower airway flow and to correlate with other airway measurements, including the forced oscillation technique. increased during illness compared with convalescence in both atopic (n 5 31) and nonatopic (n 5 11) subjects who were confirmed to have a virus detected (n 5 7 virus detected and nonatopic; n 5 16 virus detected and atopic); however, among subjects in whom a virus was not detected, this increase occurred only among atopic subjects (n 5 4 for virus not detected and nonatopic; n 5 15 for virus not detected and atopic). Asthma status (n 5 17 with asthma; n 5 25 without asthma) did not alter the increase in CD49d 1 PMNs with illness nor did the detection of virus (n 5 11 with asthma; n 5 12 without asthma). However, among subjects in whom a virus was not detected, this increase occurred only among subjects who did not have asthma (n 5 6 with asthma; n 5 13 without asthma). Boxes represent 25th to 75th percentiles of data, with the median indicated by a line. Whiskers were plotted with the Tukey method, and outliers were shown as individual circles. For all panels, the Wilcoxon signed-rank test was used to compare the median frequency of CD49d 1 PMNs between ill and well subjects. A P value of less than .05 was considered significant. *Results were still significant after multiple test adjustment by using the step-down Bonferroni method. status in all subjects (top panel: n 5 25 without asthma; n 5 17 with asthma) or in those in whom a virus was detected (middle panel: n 5 12 without asthma; n 5 11 with asthma) or was not detected (lower panel: n 5 13 without asthma; n 5 6 with asthma). Boxes represent the 25th to 75th percentiles of data, with the median indicated by a line. Whiskers were plotted with the Tukey method, and outliers were shown as individual circles. For all panels, the Mann-Whitney U test was used to compare median numbers of CD49d
1
PMNs between the 2 groups on each panel. A P value of less than .05 was considered significant. *Results were still significant after multiple test adjustment by using the step-down Bonferroni method.
